Glutamine and Insulin Sensitivity in Type I Diabetes
Status
Conditions
Treatments
Details and patient eligibility
About
Insulin is crucial to help the body metabolize ('burn') sugar (glucose). Even though juvenile (type 1) diabetes (T1D) is primarily due to the lack of insulin, patients with T1D tend to become less sensitive to insulin, particularly during adolescence.
The overall objective of this project is to gain further insight into the possible benefits of supplementation with glutamine (GLN), a natural dietary amino acid, enhancing insulin sensitivity in adolescents with T1D. To elucidate the impact of glutamine, the investigators will use a method called the 'euglycemic, hyperinsulinemic clamp': it consists of giving an IV drip of insulin, while the drop in blood sugar is prevented by giving variable, precisely measured amounts of glucose by vein: the amount of glucose required to prevent a drop in blood sugar reflects the body's sensitivity to insulin. The investigators will also give an IV drip of glucose and arginine (a building block of protein) 'tagged' with non-radioactive isotopes to better understand how glutamine may work. This procedure will be performed in 2 groups of 10 adolescents in the morning either after a strenuous exercise performed the previous afternoon (group 1; n=10), or after a sedentary day (group 2; n=10). Each subject will be studied twice, once after taking oral GLN, once after placebo, in separate clinical research center (CRC) admissions a few weeks apart, in random order.
Should the investigators hypothesis prove to be true, it would warrant long term studies to determine whether sustained dietary GLN supplementation can decrease insulin requirements and ultimately improve diabetes control in teenagers with T1DM, If successful, this approach could potentially have a significant positive impact in terms of adolescent health.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Type I diabetes diagnosed for > 12 months.
- Minimal weight of 40 kg
- Tanner stage IV or beyond
- All insulin programs, including intermediate/short acting insulins, Lantus/Detemir and short acting insulin or insulin pump therapy.
- HbA1C between 7.5 and 10%
- BMI between 10th to 85th percentile
- Patients on stable thyroid replacement therapy will be allowed to participate.
Exclusion criteria
- Celiac disease (any patient with history of positive serology or consuming a gluten-free diet)
- Cystic Fibrosis
- Chronic steroid therapy
- Chronic medications that may interfere with glucose metabolism or liver function
- History of mental retardation
- Presence of diabetic complications
- Positive pregnancy test
- Presence of significant anemia (Hb<11 g/dL)
- Presence of intercurrent infection
Trial design
Primary purpose
Allocation
Interventional model
Masking
13 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal